Skip to content

Construction of a dual-strategy of erector spinae plane block and laryngeal mask for cholecystectomy at high altitude: A multidimensional optimization study on perioperative analgesia and organ protection

Construction of a dual-strategy of erector spinae plane block and laryngeal mask for cholecystectomy at high altitude: A multidimensional optimization study on perioperative analgesia and organ protection

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113603
Enrollment
Unknown
Registered
2025-12-01
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallstone

Interventions

Group ESPB:Received ultrasound-guided bilateral T7 erector spinae nerve block, with 0.33% ropivacaine, 15 ml for each side.
Control group:General anesthesia with a simple laryngeal mask

Sponsors

Rikaze City People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 - 65 years old; 2. BMI: 18.5 - 28 kg/m^2; 3. Permanent residents of Xizang (residing at an altitude of > 3000m for >= 6 months); 4. Patients diagnosed with gallbladder stones; 5. Scheduled for laparoscopic cholecystectomy; 6. Resting SpO2 >= 85% (in high-altitude environment); 7. ASA classification: I - III grade

Exclusion criteria

Exclusion criteria: 1. Anesthesia-related contraindications (1). History of local anesthetic allergy or contraindications to the use of amide-type local anesthetics; (2). Presence of infection, deformity or space-occupying lesion in the puncture area; (3). Abnormal coagulation function (INR > 1.5 or PLT 5 points (refer to the Lake Louise standard); (3).Hematocrit (Hct) > 65% (uncontrolled high-altitude polycythemia). 4. Other exclusion factors (1). Long-term use of opioid drugs (>30mg/day morphine equivalent dose); (2). Mental illness or cognitive impairment (unable to cooperate with pain assessment); (3).Pregnant or lactating women; (4).Other situations judged by the researchers as not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
The resting VAS score;

Secondary

MeasureTime frame
The resting VAS score 1 hours after the operation;Cortisol ;Tumor necrosis factor alpha 4 hours after surgery;IL-6 level ;The amount of remifentanil used during the operation;cTnI;Oxygenation function;The time from the end of the surgery to the removal of the tube;The first post-remedy analgesic relief time;

Countries

China

Contacts

Public ContactZhang Qingfu

Rikaze People's Hospital

zhangqingfu1228@163.com+86 189 3017 3672

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026